ChemicalBook
Chinese english Germany Japanese Korea

AMPRENAVIR Produkt Beschreibung

AMPRENAVIR Struktur
161814-49-9
CAS-Nr.
161814-49-9
Englisch Name:
AMPRENAVIR
Synonyma:
PROZEI;141W94;VX 478;KVX-478;AGENERASE;AMPRENAVIR;Angenerase;Amprenavir(KVX-478);AMprenavir(agenerase);141W94, KVX-478, Agenerase, Prozei,
CBNumber:
CB4186139
Summenformel:
C25H35N3O6S
Molgewicht:
505.63
MOL-Datei:
161814-49-9.mol

AMPRENAVIR Eigenschaften

Schmelzpunkt:
72-74°C
storage temp. 
-20°C Freezer
Löslichkeit
DMSO: soluble20mg/mL, clear
Aggregatzustand
powder
Farbe
white to beige
Optische Aktivität
[α]/D +8 to +12°, c = 0.5 in methanol
InChIKey
YMARZQAQMVYCKC-OEMFJLHTSA-N

Sicherheit

RIDADR  3077
WGK Germany  3
HS Code  29350090

AMPRENAVIR Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Amprenavir was launched as Agenerase in the US for the treatment of AIDS patients in combination with approved agent antiretroviral nucleoside analogs. It is the fifth non-peptidic inhibitor of HIV-1 protease to be marketed in this indication after the last approved Neflinavir. Amprenavir, designed via a structure-based process, is the smallest molecule in the 《navir》 class and exhibits a reduced peptidic character. An improved process for preparation comprising four steps from a (1S, 2R)-2-hydroxy-3-aminopropylcarbamate has been developed. Amprenavir is a potent inhibitor of HIV-1 aspartyl protease (Ki = 0.6nM), an enzyme required by the virus to cleave pro-form polyproteins to structural proteins during the last stage in the replication process. The compound displays good oral bioavailability in humans and penetrates the CNS, which is an important advantage in long-term treatment. Its plasma half-life is approximately 10h. Treatment with Amprenavir in combination with nucleoside analog reverse transcriptase inhibitors considerably decreases viral load and restores CD4+ T-cell counts in patients with HIV infection.

Chemische Eigenschaften

Off-White to Pale Yellow

Originator

Vertex Pharm (US)

Verwenden

A selective HIV protease inhibitor. An analogue of Ritonavir

Verwenden

Protease inhibitor, anti-HIV agent

Indications

Amprenavir (Agenerase) is administered twice daily, providing the patient with an advantage over other protease inhibitors that must be taken more frequently (e.g., indinavir, saquinavir). Common side effects of am-prenavir include nausea, vomiting, diarrhea, and perioral paraesthesias. Rash occurs in approximately 20 to 30% of patients and can be mild or severe (Stevens- Johnson syndrome).

Trademarks

Agenerase (GlaxoSmithKline).

Acquired resistance

Mutations at position 50, 76 and 84 of the protease enzyme gene are associated with significantly reduced susceptibility.

Pharmazeutische Anwendungen

A synthetic compound formulated as the calcium salt of the oral prodrug fosamprenavir.

Pharmakokinetik

Oral absorption: Not known/available
Cmax 700 mg + ritonavir 100 mg:c. 6.08 mg/L
twice daily
Cmin 700 mg + ritonavir 100 mg:c. 2.12 mg/L
twice daily
Plasma half-life: c. 7.7 h
Volume of distribution: c. 430 L
Plasma protein binding: c. 90%
Absorption
Fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir and inorganic phosphate by cellular phosphatases in the gut epithelium as it is absorbed. Absolute bioavailability has not been established. It can be taken without regard to food.
Distribution
It penetrates moderately well into the CNS. The semen:plasma ratio is negligible. It is not known if it is distributed into breast milk.
Metabolism and excretion
It is extensively metabolized by the cytochrome P450 (CYP) 3A4 enzyme system. Two major metabolites have been identified that appear to result from the oxidation of the tetrahydrofuran and aniline moieties. Around 14% of a dose is eliminated in the urine and 75% in feces, <3% as unchanged drug. Metabolites account for >90% of administered drug found in fecal samples. It should be used with caution and at reduced doses in adults with mild or moderate hepatic impairment; it is contraindicated in patients with severe hepatic impairment.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Nebenwirkungen

The most common adverse events in patients receiving boosted fosamprenavir were diarrhea, nausea, headache, fatigue, vomiting and rash. Ritonavir-boosted fosamprenavir is associated with a dyslipidemia profile characteristic of those treated with other protease inhibitors boosted with 200 mg of ritonavir.

AMPRENAVIR Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


AMPRENAVIR Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 121)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
Alpha Biopharmaceuticals Co., Ltd
0086-411-39042497
0086-411-39042693 sales@alphabiopharm.com China 921 58
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19918 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 969 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23976 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 sales@jushengtech.com CHINA 28236 58
BOC Sciences
1-631-619-7922
1-631-614-7828 inquiry@bocsci.com United States 20115 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63729 58
Shanghai Hanxiang Biotechnology Co. Ltd. 15971444841
amber@biochempartner.net China 5000 58
Chengdu Lanhao Biotechnology Co., Ltd. 15397625210
1813129729@qq.com China 110 58
Shanghai Boyle Chemical Co., Ltd.
86-21-57758967 sales@boylechem.com China 2926 55

  • [(3S)-Oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
  • N-[(1S,2R)-3-[[(4-AMinophenyl)sulfonyl](2-Methylpropyl)aMino]-2-hydroxy-1-(phenylMethyl)propyl]carbaMic Acid (3S)-Tetrahydro-3-furanyl Ester
  • AMprenavir(agenerase)
  • Amprenavir(KVX-478)
  • KVX-478
  • AGENERASE
  • AMPRENAVIR
  • 141W94
  • PROZEI
  • 141W94, KVX-478, Agenerase, Prozei,
  • Carbamic acid, (1S,2R)-3-(4-aminophenyl)sulfonyl(2-methylpropyl)amino-2-hydroxy-1-(phenylmethyl)propyl-, (3S)-tetrahydro-3-furanyl ester
  • Angenerase
  • Carbamic acid, [3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, tetrahydro-3-furanyl ester, [3S-[3R*(1R*,2S*)]]-
  • VX 478
  • 161814-49-9
  • C25H35N3O6S
  • API
  • Inhibitor
  • peptides
  • Anti-viral Compounds
  • Anti-virals
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Non-nucleoside Reverse Transcriptase
  • Pharmaceuticals
Copyright 2019 © ChemicalBook. All rights reserved